Latest Balance Sheet News

Lynas Rare Earths reports FY25 revenue growth amid profit decline, completes major capital projects, and launches a $750 million equity raise to fund its expansive Towards 2030 strategy.

Lynas Rare Earths reported a 20% revenue increase in FY25 driven by higher NdPr sales, yet net profit fell sharply amid ramp-up costs and market challenges. The company completed key growth projects and unveiled its Towards 2030 strategy focused on downstream expansion.

Perpetual Limited reported a resilient FY25 with a slight dip in underlying profit, offset by strong asset growth and progress on its Simplification Program and Wealth Management sale.

BetMakers Technology Group has completed a major transformation in FY25, delivering positive adjusted EBITDA and strong operating cash flow while expanding its global footprint with a strategic US acquisition.

Perpetual Limited reported a modest 2% revenue increase for FY25, yet its net profit after tax plunged by 88%, prompting a cautious outlook despite a declared final dividend.

Lifestyle Communities reported a significant statutory loss for FY25, driven by legal provisions and asset write-downs, yet signs of recovery emerged in the second half with improved sales and cash flow.

BetMakers Technology Group delivered a strong FY25 with a 5.6% half-on-half revenue growth and record profitability, while advancing its technology transformation and signing a strategic acquisition in Nevada.

BetMakers Technology Group reported a 10.6% revenue decline to $85.1 million for FY25 but achieved positive adjusted EBITDA and operating cash flow for the first time, signaling a strategic turnaround.

Comms Group Limited reported a 2.1% revenue increase to $56.6 million for FY25, driven by organic growth and the strategic acquisition of TasmaNet. Despite this, underlying EBITDA declined 13.6%, reflecting investments and one-off revenue adjustments.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.

Lumos Diagnostics reported an 11.4% revenue increase to US$12.4 million for FY2025, yet still posted a significant net loss amid auditor concerns over its future viability.